Positive nuclear BAP1 immunostaining helps differentiate nonsmall cell lung carcinomas from malignant mesothelioma

Oncotarget

Volumn 7, Issue 37, 2016, Pages 59314-59321

  Carbone, Michele ^a   Shimizu, David ^b   Napolitano, Andrea ^a   Tanji, Mika ^a   Pass, Harvey I ^c   Yang, Haining ^a   Pastorino, Sandra ^a  

^a UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^b Queen's Medical Center   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

BAP1; Differential diagnosis; Immunohistochemistry; Lung cancer; Mesothelioma

Indexed keywords

BRCA1 ASSOCIATED PROTEIN 1; CALRETININ; CYTOKERATIN 5; MONOCLONAL ANTIBODY; NAPSIN A; PANKERATIN CAM5.2; PODOPLANIN D2-40; PROTEIN P63; THYROID TRANSCRIPTION FACTOR 1; TUMOR MARKER; UNCLASSIFIED DRUG; WILMS TUMOR 1; BAP1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN THIOLESTERASE;

ARTICLE; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MESOTHELIOMA; NON SMALL CELL LUNG CANCER; PROTEIN EXPRESSION; SQUAMOUS CELL LUNG CARCINOMA; TUMOR BIOPSY; BIOPSY; CELL NUCLEUS; IMMUNOLOGY; LUNG TUMOR; METABOLISM; PATHOLOGY; PLEURA TUMOR; SENSITIVITY AND SPECIFICITY;

BIOMARKERS, TUMOR; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; CELL NUCLEUS; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MESOTHELIOMA; PLEURAL NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN THIOLESTERASE;

EID: 84991373455     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.10653     Document Type: Article

References (41)

1. Henley SJ, Larson TC, Wu M, Antao VC, Lewis M, Pinheiro GA, Eheman C. Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003-2008 Int J Occup Environ Health. 2013; 19: 1-10. doi: 10.1179/2049396712Y.0000000016
2. U.S. Cancer Statistics Working Group. (2015). United States Cancer Statistics: 1999-2012 Incidence and Mortality Web-based Report. (Atlanta, U.S: Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute)
3. Delgermaa V, Takahashi K, Park EK, Le GV, Hara T, Sorahan T. Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ. 2011; 89: 716-24, 24A-24C. doi: 10.2471/BLT.11.086678
4. Carbone M. Simian virus 40 and human tumors: It is time to study mechanisms. J Cell Biochem. 1999; 76: 189-93
5. Carbone M, Klein G, Gruber J, Wong M. Modern criteria to establish human cancer etiology. Cancer Res. 2004; 64: 5518-24. doi: 10.1158/0008-5472.CAN-04-0255
6. Gazdar AF, Carbone M. Molecular pathogenesis of malignant mesothelioma and its relationship to simian virus 40. Clin Lung Cancer. 2003; 5: 177-81. doi: 10.3816/CLC.2003.n.031
7. Baumann F, Buck BJ, Metcalf RV, McLaurin BT, Merkler DJ, Carbone M. The Presence of Asbestos in the Natural Environment is Likely Related to Mesothelioma in Young Individuals and Women from Southern Nevada. J Thorac Oncol. 2015; 10: 731-7. doi: 10.1097/JTO.0000000000000506
8. Carbone M, Baris YI, Bertino P, Brass B, Comertpay S, Dogan AU, Gaudino G, Jube S, Kanodia S, Partridge CR, Pass HI, Rivera ZS, Steele I, et al. Erionite exposure in North Dakota and Turkish villages with mesothelioma. Proc Natl Acad Sci U S A. 2011; 108: 13618-23. doi: 10.1073/pnas.1105887108
9. Carbone M, Kanodia S, Chao A, Miller A, Wali A, Weissman D, Adjei A, Baumann F, Boffetta P, Buck B, de Perrot M, Dogan AU, Gavett S, et al. Consensus Report of the 2015 Weinman International Conference on Mesothelioma. J Thorac Oncol. 2016; 11: 1246-62. doi: 10.1016/j.jtho.2016.04.028
10. Husain AN, Colby TV, Ordonez NG, Krausz T, Borczuk A, Cagle PT, Chirieac LR, Churg A, Galateau-Salle F, Gibbs AR, Gown AM, Hammar SP, Litzky LA, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2009; 133: 1317-31. doi: 10.1043/1543-2165-133.8.1317
11. Comin CE, Novelli L, Cavazza A, Rotellini M, Cianchi F, Messerini L. Expression of thrombomodulin, calretinin, cytokeratin 5/6, D2-40 and WT-1 in a series of primary carcinomas of the lung: an immunohistochemical study in comparison with epithelioid pleural mesothelioma. Tumori. 2014; 100: 559-67. doi: 10.1700/1660.18182
12. Goldberg M, Imbernon E, Rolland P, Gilg Soit Ilg A, Saves M, de Quillacq A, Frenay C, Chamming's S, Arveux P, Boutin C, Launoy G, Pairon JC, Astoul P, et al. The French National Mesothelioma Surveillance Program. Occup Environ Med. 2006; 63: 390-5. doi: 10.1136/oem.2005.023200
13. Roushdy-Hammady I, Siegel J, Emri S, Testa JR, Carbone M. Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet. 2001; 357: 444-5. doi: 10.1016/S0140-6736(00)04013-7
14. Carbone M, Emri S, Dogan AU, Steele I, Tuncer M, Pass HI, Baris YI. A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes. Nat Rev Cancer. 2007; 7: 147-54. doi: 10.1038/nrc2068
15. Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, Cox NJ, Dogan AU, Pass HI, Trusa S, Hesdorffer M, Nasu M, Powers A, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011; 43: 1022-5. doi: 10.1038/ng.912
16. Carbone M, Flores EG, Emi M, Johnson TA, Tsunoda T, Behner D, Hoffman H, Hesdorffer M, Nasu M, Napolitano A, Powers A, Minaai M, Baumann F, et al. Combined Genetic and Genealogic Studies Uncover a Large BAP1 Cancer Syndrome Kindred Tracing Back Nine Generations to a Common Ancestor from the 1700s. PLoS Genet. 2015; 11: e1005633. doi: 10.1371/journal.pgen.1005633
17. Napolitano A, Pellegrini L, Dey A, Larson D, Tanji M, Flores EG, Kendrick B, Lapid D, Powers A, Kanodia S, Pastorino S, Pass HI, Dixit V, et al. Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma. Oncogene. 2016; 35: 1996-2002. doi: 10.1038/onc.2015.243
18. Carbone M, Yang H, Pass HI, Krausz T, Testa JR, Gaudino G. BAP1 and cancer. Nat Rev Cancer. 2013; 13: 153-9
19. Mashtalir N, Daou S, Barbour H, Sen NN, Gagnon J, Hammond-Martel I, Dar HH, Therrien M, Affar el B. Autodeubiquitination protects the tumor suppressor BAP1 from cytoplasmic sequestration mediated by the atypical ubiquitin ligase UBE2O. Mol Cell. 2014; 54: 392-406. doi: 10.1016/j.molcel.2014.03.002
20. Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, Creaney J, Lake RA, Zakowski MF, Reva B, Sander C, Delsite R, Powell S, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet. 2011; 43: 668-72. doi: 10.1038/ng.855
21. Yoshikawa Y, Sato A, Tsujimura T, Emi M, Morinaga T, Fukuoka K, Yamada S, Murakami A, Kondo N, Matsumoto S, Okumura Y, Tanaka F, Hasegawa S, et al. Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma. Cancer Sci. 2012; 103: 868-74. doi: 10.1111/j.1349-7006.2012.02223.x
22. Arzt L, Quehenberger F, Halbwedl I, Mairinger T, Popper HH. BAP1 protein is a progression factor in malignant pleural mesothelioma. Pathol Oncol Res. 2014; 20: 145-51. doi: 10.1007/s12253-013-9677-2
23. Nasu M, Emi M, Pastorino S, Tanji M, Powers A, Luk H, Baumann F, Zhang YA, Gazdar A, Kanodia S, Tiirikainen M, Flores E, Gaudino G, et al. High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma. J Thorac Oncol. 2015; 10: 565-76. doi: 10.1097/JTO.0000000000000471
24. Guo G, Chmielecki J, Goparaju C, Heguy A, Dolgalev I, Carbone M, Seepo S, Meyerson M, Pass HI. Wholeexome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res. 2015; 75: 264-9. doi: 10.1158/0008-5472.CAN-14-1008
25. Lo Iacono M, Monica V, Righi L, Grosso F, Libener R, Vatrano S, Bironzo P, Novello S, Musmeci L, Volante M, Papotti M, Scagliotti GV. Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study. J Thorac Oncol. 2015; 10: 492-9. doi: 10.1097/JTO.0000000000000436
26. Bueno R, Stawiski EW, Goldstein LD, Durinck S, De Rienzo A, Modrusan Z, Gnad F, Nguyen TT, Jaiswal BS, Chirieac LR, Sciaranghella D, Dao N, Gustafson CE, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016; 48: 407-16. doi: 10.1038/ng.3520
27. Sheffield BS, Hwang HC, Lee AF, Thompson K, Rodriguez S, Tse CH, Gown AM, Churg A. BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations. Am J Surg Pathol. 2015; 39: 977-82. doi: 10.1097/PAS.0000000000000394
28. McGregor SM, Dunning R, Hyjek E, Vigneswaran W, Husain AN, Krausz T. BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma. Hum Pathol. 2015; 46: 1670-8. doi: 10.1016/j.humpath.2015.06.024
29. Andrici J, Sheen A, Sioson L, Wardell K, Clarkson A, Watson N, Ahadi MS, Farzin M, Toon CW, Gill AJ. Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology. Mod Pathol. 2015; 28: 1360-8. doi: 10.1038/modpathol.2015.87
30. Cigognetti M, Lonardi S, Fisogni S, Balzarini P, Pellegrini V, Tironi A, Bercich L, Bugatti M, Rossi G, Murer B, Barbareschi M, Giuliani S, Cavazza A, et al. BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations. Mod Pathol. 2015; 28: 1043-57. doi: 10.1038/modpathol.2015.65
31. Tayao M, Andrici J, Farzin M, Clarkson A, Sioson L, Watson N, Chua TC, Sztynda T, Samra JS, Gill AJ. Loss of BAP1 Expression Is Very Rare in Pancreatic Ductal Adenocarcinoma. PLoS One. 2016; 11: e0150338. doi: 10.1371/journal.pone.0150338
32. Andrici J, Jung J, Sheen A, D'Urso L, Sioson L, Pickett J, Parkhill TR, Verdonk B, Wardell KL, Singh A, Clarkson A, Watson N, Toon CW, et al. Loss of BAP1 expression is very rare in peritoneal and gynecologic serous adenocarcinomas and can be useful in the differential diagnosis with abdominal mesothelioma. Hum Pathol. 2016; 51: 9-15. doi: 10.1016/j.humpath.2015.12.012
33. Fan LH, Tang LN, Yue L, Yang Y, Gao ZL, Shen Z. BAP1 is a good prognostic factor in advanced non-small cell lung cancer. Clin Invest Med. 2012; 35: E182-9
34. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 366: 883-92. doi: 10.1056/NEJMoa1113205
35. Comertpay S, Pastorino S, Tanji M, Mezzapelle R, Strianese O, Napolitano A, Baumann F, Weigel T, Friedberg J, Sugarbaker P, Krausz T, Wang E, Powers A, et al. Evaluation of clonal origin of malignant mesothelioma. J Transl Med. 2014; 12: 301. doi: 10.1186/s12967-014-0301-3
36. Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M, Sivachenko A, Sougnez C, Auclair D, Lawrence MS, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012; 150: 1107-20. doi: 10.1016/j. cell.2012.08.029
37. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, Miller ML, Rekhtman N, Moreira AL, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348: 124-8. doi: 10.1126/science.aaa1348
38. Cancer Genome Atlas Research N. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014; 511: 543-50. doi: 10.1038/nature13385
39. Cancer Genome Atlas Research N. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012; 489: 519-25. doi: 10.1038/nature11404
40. Andrici J, Parkhill TR, Jung J, Wardell KL, Verdonk B, Singh A, Sioson L, Clarkson A, Watson N, Sheen A, Farzin M, Toon CW, Gill AJ. Loss of expression of BAP1 is very rare in non-small cell lung carcinoma. Pathology. 2016. doi: 10.1016/j.pathol.2016.03.005
41. Carbone M, Ferris LK, Baumann F, Napolitano A, Lum CA, Flores EG, Gaudino G, Powers A, Bryant-Greenwood P, Krausz T, Hyjek E, Tate R, Friedberg J, et al. BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med. 2012; 10: 179. doi: 10.1186/1479-5876-10-179